Physicochemical effects of emerging exchanges on the spike protein's RBM of the SARS-CoV-2 Omicron subvariants BA.1-BA.5 and its influence on the biological properties and attributes developed by these subvariants
- PMID: 37562286
- DOI: 10.1016/j.virol.2023.109850
Physicochemical effects of emerging exchanges on the spike protein's RBM of the SARS-CoV-2 Omicron subvariants BA.1-BA.5 and its influence on the biological properties and attributes developed by these subvariants
Abstract
Emerging in South Africa, SARS-CoV-2 Omicron variant was marked by the expression of an exaggerated number of mutations throughout its genome and by the emergence of subvariants, whose attributes developed by them have been associated with amino acid exchanges that occur mainly in the RBM region of the spike protein. The RBM comprises a region within the RBD and is directly involved in the SARS-CoV-2 spike protein interaction with the host cell ACE2 receptor, during the infection mechanism and viral transmission. Defined as the region from aa 437 to aa 508, there are several residues in certain positions that interact directly with the human ACE-2 receptor during these processes. The occurrence of amino acid exchanges in these positions causes physicochemical alterations in the SARS-CoV-2 spike protein, which confer additional advantages and attributes to the agent. In addition, these exchanges serve as a basis for the characterization of new variants and subvariants of SARS-CoV-2. In this review, the amino acid exchanges that have occurred in the RBM of the subvariants BA.1 to BA.5 of SARS-CoV-2 that emerged from the Omicron are described. The physicochemical effects caused by them on spike protein are also described, as well as their influence on the biological properties and attributes developed by the subvariants BA.1, BA.2, BA.3, BA.4 and BA.5.
Keywords: Amino acid exchanges; Omicron; Physicochemical effects; SARS-CoV-2; Spike protein's RBM; Subvariants BA.1-BA.5.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.Microbiol Spectr. 2023 Mar 6;11(2):e0033323. doi: 10.1128/spectrum.00333-23. Online ahead of print. Microbiol Spectr. 2023. PMID: 36877050 Free PMC article.
-
Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion.Microb Pathog. 2022 Sep;170:105699. doi: 10.1016/j.micpath.2022.105699. Epub 2022 Aug 6. Microb Pathog. 2022. PMID: 35944840 Free PMC article. Review.
-
Computational Investigation of Selected Spike Protein Mutations in SARS-CoV-2: Delta, Omicron, and Some Circulating Subvariants.Pathogens. 2023 Dec 21;13(1):10. doi: 10.3390/pathogens13010010. Pathogens. 2023. PMID: 38276156 Free PMC article.
-
Molecular Evolutionary Analyses of the Spike Protein Gene and Spike Protein in the SARS-CoV-2 Omicron Subvariants.Microorganisms. 2023 Sep 18;11(9):2336. doi: 10.3390/microorganisms11092336. Microorganisms. 2023. PMID: 37764181 Free PMC article.
-
Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants.Drug Resist Updat. 2023 Nov;71:101008. doi: 10.1016/j.drup.2023.101008. Epub 2023 Sep 22. Drug Resist Updat. 2023. PMID: 37757651 Review.
Cited by
-
Identification and evaluation of candidate COVID-19 critical genes and medicinal drugs related to plasma cells.BMC Infect Dis. 2024 Oct 3;24(1):1099. doi: 10.1186/s12879-024-10000-3. BMC Infect Dis. 2024. PMID: 39363208 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous